Androgen-independent progression in the human prostate LNCaP tumor model is delayed by intermittent androgen suppression;Echappement hormonal et hormonothérapie intermittente dans le modèle LN CaP de cancer prostatique humain

Progres en Urologie

Volumn 6, Issue 3, 1996, Pages 375-385

  Gleave, Martin ^a,c   Santo, Nao ^b   Rennie, Paul S ^b   Goldenberg, S Larry ^b   Bruchovsky, Nicholas ^b   Sullivan, Lorne D ^b  

^a Centre for Disease Control   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c British Columbia Cancer Agnecy ^*  (Canada)

Author keywords

Intermittent androgen suppression; Lncap tumor model; Progression; Prostate cancer; Prostate specific antigen

Indexed keywords

ANDROGEN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ANIMAL; ARTICLE; BIOSYNTHESIS; BLOOD; CANCER TRANSPLANTATION; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; MOUSE; NUDE MOUSE; ORCHIECTOMY; PROSTATE TUMOR;

ANDROGENS; ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 0030167391     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. AKAKURA K., BRUCHOVSKY N., GOLDENBERG S.L., RENNIE P.S., BUCKLEY A.R., SULLIVAN L.D. Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate-specific antigen. Cancer, 1993, 71, 2782-2790.
2. BRUCHOVSKY N., RENNIE P.S., COLDMAN A.J., GOLDENBERG S L., TO M., LAWSON D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res., 1990, 50, 2275-2282.
3. CHOMCZYNSKI P., SACCHI N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Analyt. Biochem , 1987, 162, 156-159.
4. DENIS I.J., CARNEIRO D.R., MOURA J.L. Goserelin acetate and flutamide vs bilateral orchiectomy. A phase III EORTC trial (30853). Urology, 1993, 42, 119-130.
5. FARBER E. Clonal adaptation during carcinogenesis. Biochem. Pharmacol., 1990, 39, 1837-1846.
6. GLEAVE M., HSIEH J.T., WU H.C., VON ESCHENBACH A.C., CHUNG L W.K. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res., 1992, 5, 1598-1605.
7. GLEAVE M , HSIEH J.T., GAO C., VON ESCHENBACH A.C., CHUNG L.W.K. Acceleration of human prostate cancer in vivo by factors produced by prostate and bone fibroblasts. Cancer Res., 1991, 51, 3753-3761.
8. GLEAVE M.E., HSIEH J T. VON ESCHENBACH A.C., CHUNG L.W.K. Prostate and bone fibroblasts induce human prostate cancer growth in vivo : implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J. Urol., 1992, 147, 1151-1159
9. GLEAVE M.E., HSIEH J.T , WU H.C., VON ESCHENBACH A.C., CHUNG L. W.K. Evaluation of the pharmacokinetics of PSA using the LNCuP tumor model J Urol., 1992, 147, 386A.
10. GLEAVE M.E., BODEN M., GOLDENBERG S.L., BRUCHOVSKY N , SULLIVAN L.D. Predictors of androgen independent PSA progression in the LNCaP model J. Urol., 1994, 151, 248A.
11. GOLDENBERG S.L., BRUCHOVSKY N., GLEAVE M.E., SUL- LIVAN L.D , AKAKURA K. Intermittent androgen suppression in the treatment of prostate cancer : a preliminary report. Urology, 1995, 45, 839-844
12. HSIEH J.T., WU H.C., GLEAVE M.E., VON ESCHENBACH A.C., CHUNG L.W.K. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. Cancer Res., 1993, 53, 2852-2857.
13. HSIEH J.T., GLEAVE M E , WU H.C., WANG X.H., CHUNG L.W.K. Deranged control of androgen-regulated gene in the relapse stage of human prostatic cancer after castration : Implication for the derivation of androgen-independent cells by adaptive mechanisms. J. Urol., 1992, 147, 414A
14. HUGGINS C., HODGES C.V. Studies on prostate cancer. I. The effect of castration of estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1941, 1, 293-297.
15. ISAACS J.T., COFFEY D.S. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res., 1981, 41, 5070-5075.
16. ISAACS J.T., WAKE N., COFFEY D.S., SANDBERG A.A. Genetic instability coupled to clonal selection as a mechanism for progression in prostatic cancer. Cancer Res., 1982, 42, 2353-2361.
17. ISAACS J.T. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. The Prostate, 1984, 51, 1-17.
18. JANEK P., B RIAND P., HARTMAN N.R. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res , 1975, 35, 3698-3704.
19. KELLY W.K., SCHER H.I. Prostate specific antigen decline after antiandrogen withdrawal : the flutamide withdrawal syndrome. J. Urol., 1993, 149, 607-609.
20. KLOTZ L.H., KERR H.W. MORSE M.J., WHITMORE W.F. Jr. Intermittent endocrine therapy for advanced prostate cancer Cancer, 1986, 58, 2546-2550.
21. KOKONTIS J , TAKAKURA K., HAY N., LIAO S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res., 1994, 54, 1566-1573.
22. LUNDWALL A,. LILJA H. Molecular cloning of human prostate specific antigen cDNA. F.E B.S Lett., 1987, 214, 317-322.
23. MILLER J.I., AHMANN F.R., DRACH G.W., EMERSON S.S., BOTTACINI M.R. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J. Urol., 1992, 147, 956-961.
24. NOBLE R.L. The development of prostatic adenocarcinoma in the Nb rat following prolonged sex hormone administration Cancer Res., 1977, 37, 1929-1933.
25. OESTERLING J.E. Prostate specific antigen : a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 1991, 145, 907-923.
26. RENNIE P.S., BRUCHOVSKY N., BUTTYAN R., BENSON M., CHENG H. Gene expression during the early phases of regression of the androgen-dependent Shionogi mouse mammary carcinoma. Cancer Res., 1988, 48, 6309-6312.
27. RIEGMAN P.H J., VLIETSTRA R.J., VAN DER KORPUT J.A.G.M., B RINKMANN A.D., T RAPMAN J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol., 1991, 5, 1921-1930.
28. VAN WEERDEN W.M. Animal models in the study of progression of prostate and breast cancers to endocrine independency. In Mechanisms of progression to hormone-independent growth of breasdt and prostate cancer. P.M.J.J. Berns, J.C. Romijin, F H. Schroder (eds.), Parthenon Publishers, New Jersey, pp. 55-70, 1991.
29. VELDSCHOLTE J , RIS-STAPLERS C., KUIPER G.G. et al. A mutation in the ligand-binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem. Biophys. Res. Commun., 1990, 173, 534-540.
30. WU H.C., HSIEH J.T , GLEAVE M.E., CHUNG L.W.K. Characterization of growth and differentiation-associated gene activities during the progression of prostate cancer from androgen-responsive to androgen-refractory status. Cancer Res., 1992, 33, 1651A.